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Abstract The chromosomal protein HMGB1 is now regarded
as a proin£ammatory cytokine. Importantly, HMGB1 has che-
motactic activity suggesting its involvement in the early and late
events of the in£ammatory reaction. Therefore, HMGB1 has all
the hallmarks of a chemokine (chemotactic cytokine). We pro-
pose to classify HMGB1 into a new group of proteins unrelated
structurally to chemokines but having chemokine-like functions,
and to name this class CLF (chemokine-like functions). The
CLF class should include other unrelated molecules such as uro-
kinase and its receptor, cytokines macrophage migration inhib-
itory factor (MIF) and interleukin (IL)-6, anaphylatoxin C5a,
ribosomal protein S19, and thioredoxin that have similar chemo-
kine-like activities. This innovative concept may lead to the
identi¢cation of new therapeutic targets.
/ 2003 Published by Elsevier B.V. on behalf of the Federation
of European Biochemical Societies.
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1. Introduction
HMGB1 is a member of the high mobility group box
(HMGB) family of chromosomal proteins, and is well known
for its nuclear functions [1]. Recent studies have clearly dem-
onstrated surprising cytokine-like roles [2^10]. Furthermore,
HMGB1 is capable to induce chemotaxis of a variety of cells
[11^15]. Therefore, we propose to consider HMGB1 as a new
kind of chemokine (chemotactic cytokine). In this review, we
discuss the recent data that support this view.
2. HMGB1 structure
The HMGB family consists of three proteins, HMGB1,
HMGB2, and HMGB3 sharing a common structure. They
are organized into three domains, two homologous DNA
binding domains, boxes A and B, and an acidic C-terminal
domain (Fig. 1A). This domain represents the main di¡erence
between the HMGBs. HMGB1 has the longest C-terminal
domain while HMGB3 possesses the shortest. The HMG
boxes, A and B, are similar 80 amino acid segments (29%
identical, 65% similar) that form an L-shaped structure
[1]. HMGB1 is a widely expressed and very abundant
(ns 1U106 copies/cell) 215-residue single chain, 25-kDa poly-
peptide [1].
3. Nuclear functions
HMGB1 binds to the minor groove of double-stranded
DNA without apparent sequence speci¢city, but with high
a⁄nity for speci¢c DNA structures such as kinked or bent
DNA and four-way junctions (for a review see [16]). More-
over, various DNA binding proteins can recruit HMGB1 to
DNA when in need of a local deformation of DNA in order
to interact properly with their cognate binding site. In that
case, HMGB1 can bend sharply the DNA, promoting the
formation of nucleoprotein complexes and thus the interac-
tions of DNA binding proteins with their respective DNA
cognate sites [16]. This is exactly the task that HMGB1 per-
forms on behalf of p53 transcription factor [17]. p53 binds
ine⁄ciently to linear DNA, HMGB1 bends the DNA, pro-
vides it to p53 that can thus bind e⁄ciently to its sites on the
DNA sequence, then HMGB1 dissociates from the complex
[17]. HMGB1 exerts a similar role for other proteins interact-
ing with DNA that are for instance, Hox, Pou, and TBP
transcription factors, RAG1 site speci¢c recombination pro-
tein [16]. The role of HMGB1 as a regulator of transcription
is further supported by the phenotype of HMGB13=3 mice
which have a defect in the activation of GR-responsive genes
and die shortly after birth due to hypoglycemia [18].
4. Extracellular roles
Although HMGB1 (formerly HMG1 or di¡erentiation en-
hancing factor, DEF, or amphoterin) does not harbor a signal
sequence, it is released by various cells [2,3,8,15,19^22]. Its
secretion does not occur through the classical ER-Golgi route
[20,22]. In activated monocytes, HMGB1 is redistributed via a
leaderless pathway from the nucleus into secretory lysosomes,
and then released by exocytosis [22]. A similar mechanism
may apply to murine erythroleukemia (MEL) cells [19].
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Once secreted, HMGB1 stimulates cell di¡erentiation in an
autocrine, paracrine or endocrine manner [19^21].
In the brain, HMGB1 is present in the nucleus and cyto-
plasm of neuronal cells, and extracellularly. Exogenous
HMGB1 stimulates neurite outgrowth. Furthermore, anti-
HMGB1 antibodies block laminin-dependent migration of
neuroblastoma and glioma cells [11^14]. We showed that
HMGB1 stimulates migration of smooth muscle cells (SMC)
[15] and ¢broblasts (Degryse and Bianchi, unpublished re-
sults). This e¡ect is due to the presence of chemotactic epi-
tope(s) within the HMG boxes. Both boxes A and B stimulate
cell migration to a similar extent but box A requires a dose
10-fold lower than box B [15]. For the optimal concentration
of HMGB1, boxes A and B are in the nanomolar range [15]
comparable to optimal concentration of classical chemokines
[23]. The sequences of the two boxes show low level of sim-
ilarity (29%) but they have a very similar tertiary structure.
Thus, it is most likely that boxes A and B exert their chemo-
tactic e¡ects through the same receptor and mechanism of
signal transduction. This is further supported by a compara-
ble sensitivity to Bordetella pertussis toxin (PT) [15]. HMGB1
or each of its boxes also induces similar reorganization of the
actin cytoskeleton and changes of cell morphology typical of
motile cells [15].
This e¡ect of HMGB1 on cell motility may be of great
importance for diseases such as cancers. Indeed, invasion of
the surrounding tissue by tumors and metastasis require the
coordination of cell signaling to induce cell motility, and peri-
cellular proteolysis to degrade the extracellular matrix (ECM).
Interestingly, HMGB1 has been shown to stimulate cell inva-
sion, tumor growth and metastasis [24]. HMGB1 e¡ect on cell
invasion is blocked by the addition of anti-HMGB1 antibod-
ies [24]. However, the complete mechanism of action is not
known. Furthermore, HMGB1 is connected to an important
system, the plasminogen activator (PA) system, involved in
the regulation of pericellular proteolysis, cell migration, in-
£ammation, ¢brinolysis, wound healing, angiogenesis and
cancer invasion [25]. Interaction between HMGB1 and tis-
sue-type PA (tPA) stimulates plasmin formation [13,26].
HMGB1 also induces the activation of metalloproteases,
MMP-2 and MMP-9 [24]. Thus, HMGB1 may directly induce
cell motility, and indirectly promote the degradation of ECM
proteins and facilitate cell invasion.
Binding of HMGB1 to the receptor for advanced glycation
endproducts (RAGE) induces cell migration, cell invasion,
tumor growth and metastasis [15,24]. However, other recep-
tor(s) may exist. Indeed, HMGB1 interacts with a wide variety
of molecules and RAGE has not been shown to interact di-
rectly with a heterotrimeric G protein [1,13,15,26^28]. More-
over, HMGB1 is internalized and can induce di¡erentiation of
MEL cells by binding to unknown receptor(s) [29,30].
HMGB1 triggers activation of the members of the mitogen-
activated protein (MAP) kinase pathway, p38, JNK, and
ERK 1/2, and subsequently of NF-UB [15,24,31]. In addition,
both neurite extension and reorganization of actin cytoskele-
ton require the activity of small G proteins [15,31].
5. HMGB1 as a chemokine?
Cytokines are released at site of tissue injury and/or infec-
tion, and are part of the adaptive immune response as well as
the in£ammatory reaction. Chemokines are a subclass of cy-
tokines that are chemotactic. There is presently an increasing
confusion about cytokines classi¢cation created by the discov-
ery of cytokines with various structures, e¡ects and origins. In
contrast, the chemokine classi¢cation is simpler and organized
in four families, CXC, CC, C and CX3C (the letter C indi-
cates a cysteine residue, and X an unconserved amino acid)
based on the number and sequential relationship of the ¢rst
two of four conserved cysteine residues. In addition, these
small proteins share a common secondary structure exhibiting
a £exible N-terminal portion, three antiparallel L-sheets, and a
C-terminal K-helix [32]. Chemokine receptors are seven-trans-
membrane domain receptors (7TM-R) that belong to the rho-
dopsin family of G protein-coupled receptors (GPCRs) [32].
To date, about 50 chemokines and 20 receptors have been
identi¢ed implying that a number of chemokines bind to the
same receptor and that one chemokine can bind several re-
ceptors [32]. Their most characteristic function is the stimula-
tion of cell migration that is inhibited by PT indicating a
functional coupling between 7TM-R and G proteins [32]. Im-
portant downstream signaling molecules regulated by chemo-
kines are for instance phospholipase C that leads to inositol-
1,4,5-triphosphate generation, and the increase of cytosolic
Ca2þ concentrations. The MAP kinase pathway, which is an
important regulatory pathway of cell migration, is also con-
trolled by chemokines [32]. HMGB1 does not share any struc-
tural relationship with the chemokines described so far. How-
ever, HMGB1 exerts chemokine-like functions. We are going
to discuss these points now.
The cytokine-like functions of HMGB1 are well docu-
mented. This protein is a late mediator of endotoxin lethality
[2]. Lipopolysaccharide (LPS)-treated mice exhibit increased
levels of HMGB1 in the circulation, and administration of
anti-HMGB1 antibodies prevents LPS-induced mice death
[2]. Increased serum levels of HMGB1 were also observed in
human sepsis, and in one patient in hemorrhagic shock [2,33].
HMGB1 levels correlate with the severity of sepsis [2]. It has
been proposed that SPLI3=3 (secretory leukoprotease inhibi-
tor) mice have a higher mortality from endotoxin shock than
wild-type mice because SPLI3=3 macrophages produce more
HMGB1 and interleukin (IL)-6 [34]. It is striking that ethyl
pyruvate, a lipophilic pyruvate derivative, administration pre-
Fig. 1. A: Structure of HMGB1. The two HMG boxes harbor the
chemotactic epitope(s). B: A very simpli¢ed model illustrating the
role of HMGB1 in acute and chronic in£ammation.
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vents lethal sepsis and probably hemorrhagic shock in mice by
decreasing the levels of circulating HMGB1 [35]. In line with
this observation, injection of HMGB1 is lethal and reproduces
the signs of endotoxemia [2]. Moreover, HMGB1 can pro-
mote acute and chronic in£ammation, inducing acute lung
in£ammation, synovitis and arthritis [4,6,10].
The role of HMGB1 in in£ammatory diseases may be ex-
plained by its dual functions. HMGB1 can act directly by
binding to the cell inducing signaling and chemotaxis, and
indirectly by upregulating the expression and secretion of
proin£ammatory cytokines (Fig. 1B). HMGB1 is both a sig-
nal of tissue injury and a mediator of in£ammation [2,4^6,8^
10]. HMGB1 is passively released by injured or necrotic cells.
In this way, HMGB1 acts as a signaling molecule, inducing
local in£ammatory responses [8,9]. HMGB1 knockout ne-
crotic cells have a greatly decreased capacity to induce in£am-
mation [8]. On one hand, this can bene¢t to the injured tissue.
HMGB1 may initiate and modulate both early in£ammatory
steps, such as extravasation and chemotaxis of in£ammatory
cells, and late in£ammatory events, such as the chemotaxis of
cells, required to clear an infection and/or repair a tissue. On
the other hand, the in£ammatory response promoted by
HMGB1 release may lead to pathological situations. We hy-
pothesized that HMGB1 could be involved in vascular dis-
eases such as atherosclerosis and restenosis [15]. Recent data
further support our hypothesis. HMGB1 is secreted by acti-
vated monocytes and macrophages, and also released by dam-
aged or necrotic cells, leading to in£ammation [8]. In addition,
HMGB1 induces the release by the injured endothelial wall of
cytokines, chemokines and PAI-1 (PA inhibitor-1) that have
chemotactic activities [9,36]. Thus, a damaged endothelium
can induce the migration of SMC involved in vascular dis-
eases. Furthermore, in diseases such as arthritis in which mac-
rophages play a key role, chronic in£ammation may be ex-
plained by the fact that HMGB1 is released by macrophages
(Fig. 1B) [2,6].
HMGB1 may promote in£ammation by binding to RAGE
[1], but again other receptors cannot be excluded yet. For
instance, syndecan-1 is a member of the syndecan family of
transmembrane heparin sulfate proteoglycans, which play a
role as co-receptors for primary signaling receptors such as
growth factors, integrins and other adhesion receptors. Syn-
decans are involved in in£ammation and are capable to reg-
ulate leukocyte tra⁄cking [37].
We already mentioned the correlation between the in£am-
matory reaction and the expression of HMGB1. Cytokines
and LPS induce HMGB1 release [2,3,38]. The opposite rela-
tionship has also been proven to be true. HMGB1 can regu-
late cytokine expression [4,5,7^9,10,39].
As a chemokine, HMGB1 should control the activation and
chemotaxis of leukocytes. HMGB1 exerts these functions.
HMGB1 expression is an activation event for neutrophils
and monocytes/macrophages [5,10,39]. Recruitment of in£am-
matory cells through the endothelium and into the in£amma-
tory foci requires adhesion and transmigration through the
endothelium and the ECM. HMGB1 modulates the expres-
sion of adhesion molecules that facilitate the extravasation of
monocytes/macrophages [9]. Importantly, HMGB1 generates
a chemotactic signal by binding to the cell. HMGB1 promotes
migration of adherent cells such as ¢broblasts and SMC, and
the recruitment of in£ammatory cells such as neutrophils,
monocytes and macrophages [4,6,8,10,15]. It has been sug-
gested recently that the HMG boxes A and B have di¡erent
properties, box A has an anti-in£ammatory while box B has a
proin£ammatory activity [40]. In our hands, both boxes were
equally chemotactic [15]. Last, HMGB1 can regulate the pro-
teolytic activity needed for the degradation of the components
of the ECM through its connection with the PA system and
metalloproteases (see above).
In conclusion, like classic chemokines, HMGB1 is a chemo-
tactic and immunoregulatory protein, which can promote an
e¡ective in£ammatory immune response. The connection be-
tween HMGB1 and a 7TM-R is not proven yet. However,
HMGB1-induced cell migration is achieved through a hetero-
trimeric G protein-dependent mechanism, and activation of
the MAP kinase pathway, which are both generally activated
by chemokine receptors. Therefore, HMGB1 has all the hall-
marks of a proin£ammatory chemokine. We propose to mod-
ify the chemokine classi¢cation based only on the presence of
speci¢c CXC, CC, C or CX3C (C indicates a cysteine residue)
motifs in the sequence of the proteins. A new class of chemo-
kines unrelated structurally to ’cysteine’ chemokines but ex-
erting chemokine-like functions should be created. We pro-
pose to name this new class of proteins CLF (chemokine-
like functions). Another possible name for this class is
HULCK (highly unconventional chemokine).
6. Other CLF chemokines
The CLF class should include other proteins that have also
chemokine-like functions. We brie£y present a few other CLF
chemokines.
6.1. Urokinase (uPA) and its receptor (uPAR)
uPA and uPAR are certainly among the best CLF candi-
dates (Table 1). uPA is a serine protease that binds to cell
surface through uPAR, a glycosyl-phosphatidyl-inositol
(GPI)-anchored protein. By binding to uPAR, uPA induces
a conformational change of uPAR resulting in the exposition
of a chemotactic epitope located in the linker region of uPAR
[25]. This change turns uPAR into a ligand of FPRL1, the low
a⁄nity 7TM-R for fMLP, which in turn stimulates cell migra-
tion [25]. Like chemokines, uPA/uPAR-dependent signaling is
PT sensitive suggesting the involvement of a heterotrimeric G
protein and leads to the activation of the MAP kinase path-
way [25,41,42]. Both proteins play important roles in in£am-
mation that have been documented by in vitro and in vivo
studies (for a review see [25]). Recruitment of in£ammatory
cells is de¢cient in uPA3=3 mice. In human, the expression of
uPA correlates with the severity of in£ammation in several
diseases. uPA expression is also an activation event for macro-
phages and lymphocytes, regulating cytokine expression. Con-
versely, cytokines and LPS increase uPA expression. Further-
more, uPA is a strong chemoattractant promoting migration
of adherent and non-adherent cells such as SMC, ¢broblasts,
macrophages and lymphocytes [25].
uPAR has already been proposed to be a membrane-asso-
ciated chemokine [41,43]. uPAR possesses most of the chemo-
kine-like properties of uPA (Table 1) [25]. uPAR is an acti-
vation antigen of T lymphocytes. uPAR expression is
increased in several diseases such as acute myocardial infarc-
tion and high levels are found in the circulation of patients
su¡ering of various cancers and HIV infections. In addition,
uPAR is released during sepsis, endotoxemia, and rheumatoid
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arthritis. uPAR is upregulated by LPS, formylated peptides
and cytokines [25]. However, this receptor has other ligands,
such as vitronectin, a protein of the ECM that promotes cell
adhesion and migration, and high molecular kinin-free kini-
nogen (HKa) that inhibits cell adhesion [25]. Thus, it is not
surprising that uPAR3=3 and uPA3=3 mice have di¡erent
phenotypes. For instance, leukocyte recruitment during acute
in£ammation, but not during long term in£ammation, is dras-
tically reduced in uPAR3=3 mice, whereas it is completely
abrogated in both cases in uPA3=3 mice [25]. Finally, in con-
trast to classical chemokines, uPA/uPAR induce chemotaxis
of all leukocytes.
6.2. Macrophage migration inhibitory factor (MIF)
MIF was ¢rst identi¢ed as a T cell-derived inhibitor of
random cell migration of macrophages [44,45]. However,
MIF has a unique characteristic, it is produced by the anterior
pituitary gland and may be considered as a hormone that acts
as a counterregulator of glucocorticoids [44,45]. MIF expres-
sion is induced by low dose of glucocorticoids and antago-
nizes their anti-in£ammatory e¡ects. Yet, MIF is also recog-
nized as a proin£ammatory cytokine and has chemokine-like
functions (Table 1). As a cytokine, MIF can activate macro-
phages inducing the production of tumor necrosis factor
(TNF)-K, IL-1, IL-6 and IL-8. Conversely, TNF-K, IL-1,
IL-6, IL-8, and IL-12 induce MIF production by macro-
phages. MIF is also released by various cells including T cells,
and endothelial cells. Surprisingly, MIF seems to play a role
similar to HMGB1 in sepsis [44,45]. In mice, MIF exacerbates
the lethal e¡ect of LPS, whereas anti-MIF antibody protects
against lethal peritonitis, exotoxemia, and endotoxemia
[44,45]. Recruitment of neutrophils is reduced in LPS-treated
rats by the administration of anti-MIF antibody [44] protect-
ing against acute lung injuries. Similarly, anti-MIF antibody
can also protect against LPS-induced acute liver injury [44].
Furthermore, MIF3=3 mice are resistant to septic shock in-
duced by high doses of LPS [44,45], and show decreased levels
of TNF-K than their wild-type counterparts. Again surpris-
ingly similar to HMGB1, MIF seems to be involved in wound
healing, tumor growth, angiogenesis [44,45], and regulates
chemotaxis [46,47]. MIF induces the production of MMPs
enabling tumors growth and metastasis but also inducing tis-
sue damages observed for instance in chronic in£ammatory
diseases such as arthritis. The mechanism of action of MIF is
poorly understood. CD74 (or Ii, IQ), MHC class II-associated
invariant chain, has been recently identi¢ed as a cell receptor
for MIF [48]. CD74 is a type 2 transmembrane receptor and
so far, no interaction has been described between CD74 and
an eventual 7TM-R and/or a G protein. MIF has been shown
to activate p38, and p44/42 (ERK 1/2) MAP kinases, the latter
in a CD74-dependent manner [48].
6.3. C5a anaphylatoxin and S19 ribosomal protein
The complement is a complex cascade of the immune sys-
tem that leads to the elimination of the antigen and/or patho-
gen. Three pathways trigger complement activation. The clas-
sical pathway is activated by immune complex, the lectin
pathway by the recognition of microbial carbohydrates by
mannose binding lectin, and the alternative pathway by pat-
tern recognition of foreign surfaces (for reviews see
[45,49,50]). These pathways converge on C3, the central mol-
ecule of the complement. Cleavage of C3 leads through suc-
cessive steps to the formation of C5b-9, the membrane attack
complex [45,49,50]. Cleavage of C5 generates a byproduct, the
anaphylatoxin C5a which promotes several proin£ammatory
e¡ects such as SMC contraction, enhanced vascular perme-
ability, vasodilatation, release of granular enzymes and sec-
ondary in£ammatory mediators by phagocytic cells, produc-
tion of oxidase activities in neutrophils and eosinophils
[45,49,50]. C5a is also a strong chemoattractant (Table 1)
that recruits a wide variety of leukocytes [45,49,50]. Further-
more, C5a induces the release of cytokines and chemokines
including TNF-K, IL-1, IL-6, IL-8, IL-12 [50]. Thus, comple-
ment activation is associated with in£ammatory disorders in-
cluding sepsis. During sepsis, an overactivation of the comple-
ment generates an excess of C5a that results in explosive
proin£ammatory responses leading to tissue injury, multi-or-
gan failure, and death [45,49,50]. In mice and rats, adminis-
tration of antibodies against C5a or its receptor C5aR e¡ec-
tively protects against septic lethal shock [45]. This correlates
with decreased levels of TNF-K and IL-6 [45]. C5a acts by
binding to C5aR (CD88), a 7TM-R coupled to both PT-sen-
Table 1
Properties of CLF chemokines compared to a classic inducible chemokine
HMGB1 uPA uPAR MIF C5a RP S19d Trx IL-6 Inducible
chemokine
Release under
in£ammatory
conditions
yes yes, release is increased,
but secreted not only in
in£ammatory conditions
expression increased yes yes yes yes yes yes
Expression upregulated
by cytokine
yes yes yes yes no ? no yes yes
Engage a speci¢c
subpopulation of
leukocytes
yes stimulate all leukocytes stimulate all
Leukocytes
yes yes yes yes yes yes
Bind to a 7TM-R no (?) bind to uPAR which in
turn bind to FPRL1, a
7TM-R
yes no (?) yes yes no no yes
Signal via a hetero-
trimeric G protein
yes yes yes no (?) yes yes no no yes
Activate MAP kinase
pathway
yes yes yes yes yes ? ? yes yes
Regulate cytokine
expression
yes yes yes yes yes ? yes yes yes
Activate leukocytes yes yes yes yes yes ? yes yes yes
Chemotactic yes yes yes yes yes yes yes yes yes
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sitive and -insensitive G proteins [49]. By binding to C5aR,
C5a activates p44/42 MAP kinases [51]. C5aR is expressed in
leukocytes but also in other cells such as SMC, endothelial
and epithelial cells.
The S19 ribosomal protein is a protein of the mRNA trans-
lation machinery leading to protein synthesis. However, as a
cross-linked homodimer (RP S19d), it has a very di¡erent role
[52,53]. RP S19d has been ¢rst puri¢ed from a rheumatoid
arthritis synovial lesion suggesting a possible role in in£am-
mation. This hypothesis was further supported by the ¢nding
that RP S19d is another ligand of C5aR. Furthermore, RP
S19d is released by apoptotic cells [54], and is a chemoattrac-
tant for monocytes and macrophages [52,53]. In contrast to
C5a, RP S19d is an antagonist of C5aR in polymorphonu-
clear leukocytes [53] inhibiting their chemotaxis. These data
suggest that RP S19d might be involved in the recruitment of
monocytes/macrophages into the apoptotic site, and promote
in this way the clearance of apoptotic cells [52]. Thus, pre-
venting tissue damage, in£ammation, and autoimmune reac-
tions. Too few data are presently available and further inves-
tigations are necessary to precise its role. Nevertheless, RP
S19d represents a very good potential CLF chemokine (Table
1).
6.4. IL-6
IL-6 is a hematopoietin cytokine that exerts pleiotropic ef-
fects and plays a crucial role in cell growth, di¡erentiation,
survival, acute phase protein production, fever, in£ammation,
tumor growth and cell migration [55^57]. IL-6 is produced by
a wide variety of cells including T cells, B cells, monocytes,
¢broblasts, keratinocytes, endothelial cells, mesangial cells,
SMC, and tumor cells. IL-6 induces also the production of
cytokines and chemokines including IL-2, IL-8, MCP-1, and
MCP-3, and depending on cell types, LPS, cytokines, IL-1,
IL-4, TNF-K, interferon (IFN)-Q, tumor growth factor (TGF)-
L, and chemokines such as MCP-1 (CCL2), and RANTES
(CCL5) promote IL-6 synthesis (for a review see [56]). As a
growth factor, IL-6 induces growth and/or di¡erentiation of
various cells, megakaryocytes, hematopoietic stem cells, osteo-
clasts, B cells, hepatocytes, T cells, PC-12 cells, myeloma cells,
keratinocytes and mesangial cells. Importantly, IL-6 is a che-
moattractant (Table 1) for SMC, osteoclasts, adherent lym-
phokine-activated killer cells, lymphocytes, and carcinoma
cells [55,56]. In agreement with its growth factor and chemo-
attractant functions, the healing of skin wounds is dramati-
cally delayed in IL-63=3 mice [57]. In addition, IL-6 enhances
IL-1-induced production of MMPs and thus may promote
tissue invasion. Due to decreased chemokine production, re-
cruitment of neutrophils is defective in IL-6-de¢cient mice but
can be restored by the administration of IL-6 [55]. IL-63=3
mice are also protected against joint in£ammation and tissue
damages resulting from arthritis [56]. In line with these data,
in wild-type mice, antibodies against IL-6R (IL-6 K-receptor
subunit) prevent these disease-induced damages [56]. On the
other hand, IL-6 has also anti-in£ammatory activity. In LPS-
treated rats, injection of IL-6 decreased the levels of TNF-K
and synthesis of IL-1. In an animal model of endotoxin lung
injury and endotoxemia, levels of TNF-K were higher in IL-
63=3 than in wild-type mice [56]. The mechanism of signal
transduction is very particular, and initiated by the binding
of IL-6 to IL-6R, which has no signaling activity. Then, the
IL-6^IL-6R complex recruits the transducer gp130 [56]. The
resulting IL-6^IL-6R^(gp130)2 complex leads to the activation
of the downstream MAP kinase signaling cascade and other
pathways [56]. However, no link has been reported between
IL-6 signaling and 7TM-R and/or G protein. Unlike gp130,
the expression of IL-6R is limited. Nevertheless, a soluble
form of IL-6R (sIL-6R) exists in the circulation and higher
levels have been observed in chronic arthritis and other patho-
logic conditions [56]. Thus, IL-6^sIL-6R complex can act on
cells devoid of IL-6R transforming them in IL-6-responsive
cells [56]. A soluble form of gp130 has also been found [56]. In
that case, interactions between sgp130 and IL-6^sIL-6R will
certainly antagonize the e¡ect of IL-6.
6.5. Thioredoxin (Trx)
Trx, or adult T cell leukemia-derived factor (ADF) is cer-
tainly a good example of CLF chemokine (Table 1). Indeed,
Trx exhibits cytokine-like and chemokine-like activities
([23,58], for a review see [59]). It is striking that Trx shares
several characteristics with HMGB1. Both are ubiquitously
expressed, and their cellular distribution is also almost similar.
Trx is present in the cell nucleus, cytoplasm, mitochondria,
and also in the extracellular compartment [59]. In addition,
the secreted Trx has no signal peptide, and does not follow
the classical ER-Golgi route [59]. Furthermore, Trx also reg-
ulates the DNA binding activity of redox-sensitive transcrip-
tion factors NF-UB, APC-1, p53, CREB, PEBP2/CBF, Myb,
and both estrogen and glucocorticoid receptors [59]. However,
Trx has speci¢c characteristics. As a dithiol-disul¢de oxidore-
ductase, Trx catalyzes the reduction of disul¢des. Trx is a key
player in keeping intracellular protein disul¢des in their re-
duced state [59]. As a cytokine, Trx induces IL-2 receptor, and
activates eosinophil functions, cytotoxicity and migration.
Moreover, Trx exerts proin£ammatory e¡ects promoting cy-
tokines, such as TNF, release by ¢broblasts and monocytes
[59]. The chemokine-like activities of Trx are well illustrated
by its potent chemotactic e¡ect on neutrophils, monocytes
and T cells [23]. In addition, Trx has been found partially
responsible for the chemotactic activity release by human T
cell leukemia/lymphoma virus (HTLV)-1-infected cells [23].
The chemotactic activity is harbored by the CXXC active
site of the enzyme that forms a disul¢de in the oxidized
form or a dithiol in the reduced form. Indeed, mutation of
cysteines of the active site results in the loss of chemotactic
activity [23]. The exact mechanism of signal transduction is
not known. However, it has been shown that it is G protein
independent and unlike classical chemokines does not require
a 7TM-R [23]. Stress stimuli such as hypoxia, ultraviolet (UV)
irradiation, X-ray radiation, oxidants such as hydrogen per-
oxide, phorbol ester, molecules increasing intracellular cAMP
such as forskolin, infectious agents, hormones, chemicals, and
LPS induce Trx production. Trx is released by various cells,
for instance keratinocytes, melanocytes, monocytes, IFN-Q or
LPS-activated macrophages and activated T lymphocytes as
well as other normal and neoplastic cells [59]. Trx is upregu-
lated in diseases associated with oxidative stress, for example
in cerebral ischemia, brain injury, and open-heart surgery. In
the circulation, high level of Trx is a marker of poor prognosis
in HIV infection. Elevated levels of Trx are also observed in
hepatitis C virus infection, synovial £uid of rheumatoid arthri-
tis, and cancer [59]. Trx has also anti-in£ammatory activities.
Trx protects against hydrogen peroxide and hypoxia, and
suppresses LPS-induced neutrophil adhesion and chemotaxis
FEBS 27676 24-9-03
B. Degryse, M. de Virgilio/FEBS Letters 553 (2003) 11^17 15
[58,59]. Furthermore, since chemokine pretreatment induces
desensitization and thus inhibits chemotaxis, elevated levels
of Trx have been shown to inhibit neutrophil and monocyte
recruitment [58]. However, the mechanism of desensitization is
unclear because Trx does not act through a 7TM-R and/or G
proteins. Few data are available on the intracellular e¡ectors
and signaling pathways controlled by Trx. Apoptosis signal-
ing-regulating kinase 1 (ASK1) is negatively regulated by Trx,
thus preventing apoptosis [59].
Trx80, a truncated form of Trx produced by monocytes,
has been puri¢ed in human peripheral blood mononuclear
cell (PBMC) cultures. Trx80 lacks the C-terminal part of
Trx, and consists of the 80 N-terminal residues of the protein.
Trx80 (most likely identical to eosinophilic cytotoxicity en-
hancing factor, ECEF), active as a dimer, has speci¢c charac-
teristics [60]. For instance, Trx80 stimulates eosinophilic cell
cytotoxicity, and proliferation and activation of monocytes.
Trx80, through secretion of IL-12, is also indirectly mitogenic
for T lymphocytes [60].
7. Conclusions
In this review, we propose to create a new class of chemo-
kines, named CLF, which groups presently together eight pro-
teins. This list will probably expand. This new classi¢cation,
required by the need to give to proteins such as HMGB1 a
proper and well-deserved status, is based only on functions.
CLF chemokines do not share the traditional structures of
classical CXC, CC, C or CX3C chemokines. Table 1 summa-
rizes the characteristics of all CLF chemokines presented here,
and compares them to a classical chemokine. It is puzzling
that these unrelated proteins that have very di¡erent primary
roles (Table 2) can exert similar chemokine-like functions,
basically recruitment and activation of leukocytes. It appears
that these basic roles are achieved through various receptor
types and signal transduction mechanisms as shown by di¡er-
ent sensitivity to PT. However, the generated signals converge
inside the cell and result in the activation of the MAP kinase
pathway. Yet, some molecules have not been thoroughly
studied, and future research might reveal more shared char-
acteristics. Nevertheless, it is already possible to distinguish a
common pattern. CLF chemokines are multifunctional pro-
teins that exert various well-de¢ned primary roles, and under
special circumstances can exhibit chemokine-like functions as
secondary roles (Table 2). This idea may better be illustrated
by the other proposed family name, HULCK. They target not
only leukocytes but also other normal or neoplastic cell types.
Since CLF chemokines are ubiquitous or widely expressed,
they can serve in order to obtain optimally adapted cellular
responses, as convenient signals to transmit to immune cells
and to the surrounding tissue the occurrence of a particular
event (Table 2), for instance, tissue injury or necrosis in the
case of HMGB1.
CLF class represents an innovative concept that may
change our traditional view of chemokines and in£ammation,
and may lead to the identi¢cation of new therapeutic targets.
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